Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
· The Strategic Collaboration Agreement will enable both parties to utilise extensive knowledge sharing for microbiome diagnostics and biotherapeutics development · Genetic Analysis is a Norway-based diagnostic company and a pioneer in the human microbiome field, Servatus is a leading biopharmaceutical company with research and manufacturing facilities in Australia · Global human microbiome market expected to reach USD$965.6 million by 2029 · First stage of agreement is to establish a ‘GA-map® Flagship Lab’ fully operational for microbiome analysis in Servatus’ Queensland